LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

A wide-reaching Trump Administration order disrupted systems nationwide and left millions unsure if they will lose access to jobs, housing and health care. Institutions in Long Beach are scrambling to ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that it has received the necessary independent ethics board approval required for its contract research organization ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...